share_log

Clover Health | 8-K: Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Clover Health | 8-K: Clover Health Reports Strong Third Quarter 2024 Financial Results; Highlights Differentiated Market Opportunity to Grow Membership

Clover Health | 8-K：三葉草健康公佈了強勁的2024年第三季度財務業績；強調了增加會員人數的差異化市場機會
美股SEC公告 ·  11/07 05:12

牛牛AI助理已提取核心訊息

Clover Health reported robust Q3 2024 financial results, with total revenue growing 8.2% YoY to $331.0M. Insurance revenue increased 7.1% to $322.6M, driven by strong member retention and intra-year growth. The company significantly improved its GAAP Net Loss from continuing operations to $8.8M from $33.6M in Q3 2023.Adjusted EBITDA surged to $19.3M from $2.7M last year, reflecting enhanced operational efficiency. The Insurance MCR improved to 78.0% from 78.5% YoY, while the Insurance BER decreased to 82.8% from 83.3%. Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55M-$65M, up from the previous $50M-$65M range.CEO Andrew Toy highlighted the company's strong performance amid industry headwinds, attributing success to their technology-driven approach. CFO Peter Kuipers noted that the improved financial profile, combined with strong Stars performance for their flagship PPO plan, positions the company well for membership growth in 2025.
Clover Health reported robust Q3 2024 financial results, with total revenue growing 8.2% YoY to $331.0M. Insurance revenue increased 7.1% to $322.6M, driven by strong member retention and intra-year growth. The company significantly improved its GAAP Net Loss from continuing operations to $8.8M from $33.6M in Q3 2023.Adjusted EBITDA surged to $19.3M from $2.7M last year, reflecting enhanced operational efficiency. The Insurance MCR improved to 78.0% from 78.5% YoY, while the Insurance BER decreased to 82.8% from 83.3%. Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55M-$65M, up from the previous $50M-$65M range.CEO Andrew Toy highlighted the company's strong performance amid industry headwinds, attributing success to their technology-driven approach. CFO Peter Kuipers noted that the improved financial profile, combined with strong Stars performance for their flagship PPO plan, positions the company well for membership growth in 2025.
Clover Health報告了2024年第三季度強勁的財務結果，總營業收入同比增長8.2%，達到33100萬。保險營業收入增長7.1%，達到32260萬，這得益於強大的會員留存和年度增長。公司的GAAP持續經營淨虧損顯著改善，從2023年第三季度的3360萬減少至880萬。經調整的EBITDA從去年的270萬大幅上升至1930萬，反映出提升的運營效率。保險的MCR同比改善至78.0%，低於78.5%；而保險的BER則從83.3%下降至82.8%。Clover Health將2024年的全年經調整EBITDA指引上調至5500萬至6500萬，高於之前的5000萬至6500萬的區間。首席執行官Andrew Toy強調了公司在行業逆風中的強勁表現，將成功歸因於其以科技驅動的方法。財務長Peter Kuipers指出，改善的財務狀況，加上其旗艦PPO計劃的強勢Stars表現，爲2025年的會員增長奠定了良好的基礎。
Clover Health報告了2024年第三季度強勁的財務結果，總營業收入同比增長8.2%，達到33100萬。保險營業收入增長7.1%，達到32260萬，這得益於強大的會員留存和年度增長。公司的GAAP持續經營淨虧損顯著改善，從2023年第三季度的3360萬減少至880萬。經調整的EBITDA從去年的270萬大幅上升至1930萬，反映出提升的運營效率。保險的MCR同比改善至78.0%，低於78.5%；而保險的BER則從83.3%下降至82.8%。Clover Health將2024年的全年經調整EBITDA指引上調至5500萬至6500萬，高於之前的5000萬至6500萬的區間。首席執行官Andrew Toy強調了公司在行業逆風中的強勁表現，將成功歸因於其以科技驅動的方法。財務長Peter Kuipers指出，改善的財務狀況，加上其旗艦PPO計劃的強勢Stars表現，爲2025年的會員增長奠定了良好的基礎。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間